CompletedPhase 2NCT00580034

Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath

Studying Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
David Rizzieri, MD
Principal Investigator
David Rizzieri, MD, PA-C
Duke Health
Intervention
Campath Purged Non-myeloablative ASCT(drug)
Enrollment
176 enrolled
Eligibility
17 years · All sexes
Timeline
20032013

Study locations (1)

Collaborators

Miltenyi Biomedicine GmbH

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00580034 on ClinicalTrials.gov

Other trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Additional recruiting or active studies for the same condition.

See all trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

← Back to all trials